行业分析 |
|
|
|
|
基因治疗行业市场分析及展望* |
冯雪娇1,**(),衡超1,于新语2,王俊姝1 |
1 江西省科学院科技战略研究所 南昌 330096 2 南昌大学公共政策与管理学院 南昌 330031 |
|
Market Analysis and Prospect of Gene Therapy Industry |
FENG Xue-jiao1,**(),HENG Chao1,YU Xin-yu2,WANG Jun-shu1 |
1 Institute of Science and Technology Strategy, Jiangxi Academy of Sciences, Nanchang 330096,China 2 School of Public Policy and Administration, Nanchang University, Nanchang 330096, China |
引用本文:
冯雪娇, 衡超, 于新语, 王俊姝. 基因治疗行业市场分析及展望*[J]. 中国生物工程杂志, 2023, 43(6): 102-112.
FENG Xue-jiao, HENG Chao, YU Xin-yu, WANG Jun-shu. Market Analysis and Prospect of Gene Therapy Industry. China Biotechnology, 2023, 43(6): 102-112.
链接本文:
https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.2304027
或
https://manu60.magtech.com.cn/biotech/CN/Y2023/V43/I6/102
|
[1] |
Gruntman A M, Flotte T R. The rapidly evolving state of gene therapy. The FASEB Journal, 2018, 32(4): 1733-1740.
doi: 10.1096/fsb2.v32.4
|
[2] |
Cho S W, Kim S, Kim J M, et al. Targeted genome engineering in human cells with the Cas 9 RNA-guided endonuclease. Nature Biotechnology, 2013, 31(3): 230-232.
doi: 10.1038/nbt.2507
|
[3] |
Ginn S L, Amaya A K, Alexander I E, et al. Gene therapy clinical trials worldwide to 2017: an update. J Gene Med, 2018, 20: e3015.
doi: 10.1002/jgm.v20.5
|
[4] |
Weβ L, Schnieders F. Immuno-oncology-the translational runway for gene therapy: gene therapeutics to address multiple immune targets. Human Gene Therapy, 2017, 28(12): 1130-1137.
doi: 10.1089/hum.2017.145
pmid: 29061083
|
[5] |
Wei J, Xiao M, Mao Z K, et al. Outcomes of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (r/r B-NHL) patients with TP53 gene disruption treated with CD19/22 cocktail CAR T-cell therapy alone or incorporated with autologous stem cell transplantation (ASCT). Blood, 2021, 138: 94.
doi: 10.1182/blood-2021-147278
|
[6] |
Ma C C, Wang Z L, Xu T, et al. The approved gene therapy drugs worldwide: from 1998 to 2019. Biotechnology Advances, 2020, 40: 107502.
doi: 10.1016/j.biotechadv.2019.107502
|
[7] |
张永理, 张开然. 我国罕见病患者医疗保障现状及改进建议. 卫生经济研究, 2023, 40(1):53-56, 60.
|
|
Zhang Y L, Zhang K R. Medical security status and improvement suggestions for patients with rare diseases in China. Health Economics Research, 2023, 40(1):53-56, 60.
|
[8] |
Zheng R S, Zhang S W, Zeng H M, et al. Cancer incidence and mortality in China, 2016. Journal of the National Cancer Center, 2022, 2(1): 1-9.
doi: 10.1016/j.jncc.2022.02.002
|
[9] |
解国涛, 晏贤春, 韩骅, 等. 单碱基编辑技术在单基因遗传病治疗中的应用研究进展. 基因组学与应用生物学, 1-18.[2023-05-29]. http://kns.cnki.net/kcms/detail/45.1369.Q.20230130.1442.001.html.
|
|
Xie G T, Yan X C, Han H, et al. Research progress on the application of single base editing technology in the treatment of single gene genetic diseases. Genomics and Applied Biology, 1-18.[2023-05-29]. http://kns.cnki.net/kcms/detail/45.1369.Q.20230130.1442.001.html.
|
[10] |
刘旭, 仲祉霖, 钟涛. 碱基编辑器的研发及其应用. 中国细胞生物学学报, 2022, 44(12):2294-2304.
|
|
Liu X, Zhong Z L, Zhong T. Development and application of base editor. Chinese Journal of Cell Biology, 2022, 44(12):2294-2304.
|
[11] |
刘尧, 周先辉, 黄舒泓, 等. 引导编辑: 突破碱基编辑类型的新技术. 遗传, 2022, 44(11): 993-1008.
|
|
Liu Y, Zhou X H, Huang S H, et al. Prime editing: a search and replace tool with versatile base changes. Hereditas (Beijing), 2022, 44(11): 993-1008.
|
[12] |
Friedmann T, Roblin R. Gene therapy for human genetic disease? Science, 1972, 175(4025): 949-955.
doi: 10.1126/science.175.4025.949
pmid: 5061866
|
[13] |
陈伟伟, 杨胜果, 刘毅. 人体胚胎基因编辑的伦理及法律问题研究: 以 “基因编辑婴儿” 事件为分析对象. 科技与法律, 2019(2): 61-65, 73.
|
|
Chen W W, Yang S G, Liu Y. Study on ethical and legal issues of human embryo gene editing: taking the event of “genetically-edited babies” as the analysis object. Journal of Science, Technology and Law, 2019(2): 61-65, 73.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|